Friday, February 24, 2017 2:59:09 PM
Hi Thomas,
Thank you very much for reaching out, it has been a few months. Yes, we realize investors want an update but to be honest we are a bit confused. We feel with the new website and letting everyone know when a new practice comes on board is the most important piece of information investors could receive at this point. The more doctors, the more acceptance and the more potential for revenue. We felt we have been providing more information on a regular basis now than in the past 5 years. With over 40 clinics now offering the INVO Procedure we feel we are little a head of the game but still only time will tell.
We decide not to do an update because we will just get bashed for not having the financials done. It will be taken as a negative not a positive, so why detract from the things we have and want to get done. We will do the financials 1st then see if an update is needed. We continue doing exactly what we outlined to everyone a year ago, work with doctors to offer INVO, get the financials caught up with the SEC and then go out and raise the proper funding to really grow the Company. Still doing what we said just taking a bit longer, as most things in life.
As we stated in the house keeping 8-K we filed last month, we will be submitting the 5 year 10-K through 12/31/15 to the SEC soon. It in now in the attorney's hands and we have had a couple of re-iterations with them making sure we have captured everything.
Once done at the lawyers we will continue to follow the normal filing process as any company does. It will be sent to the Board for their review and signature and to be Edgarized. Once signed off, we will have it XBRL'd, a final review and then filed. So we are very close, I would say within a couple of weeks, depends on the Board review.
As most calendar year end companies are now, I have already started working with the audit firm on the 2016 audit, shooting to get that filed on time which is 3/31/17.
We will continue with on with what we told everyone, next on the plate will be to update the business plan with the most current data and go raise funds.
Thank you again for your continued support.
Take care,
Rob
Robert J. Bowdring
Director
INVO Bioscience Inc.
Office/Fax - 978-878-9505 ext.508
www.INVOBioscience.com
The end is near!
Everyone have a great weekend.
Cburg
Recent INVO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:30:18 PM
- Micro Cap Massively Bid Up Before Opening Bell • AllPennyStocks.com • 04/17/2024 02:25:00 PM
- INVO Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/16/2024 08:59:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:24:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:01:07 PM
- NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 01/16/2024 10:29:59 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/10/2024 09:46:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:05:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:29:45 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 12/28/2023 10:04:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 10:02:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/13/2023 10:08:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:53:21 PM
- NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal • PR Newswire (US) • 12/11/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 10:18:38 PM
- INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • PR Newswire (US) • 11/28/2023 02:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/24/2023 06:08:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:59:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:10:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:06:04 PM
- INVO Reports Record Third Quarter 2023 Financial Results • PR Newswire (US) • 11/13/2023 09:01:00 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 11/13/2023 02:23:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:21:54 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM